XML 64 R51.htm IDEA: XBRL DOCUMENT v3.7.0.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Mar. 31, 2017
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
License agreements                  
Research and development expense             $ 407,972 $ 156,824  
Unrealized loss on long term investments             (5,814) (2,950)  
Long term investment             $ 158,322   $ 31,987 [1]
Agenus                  
License agreements                  
Number of program targets | item       3   4      
Royalty payments on future global net sales (as a percent)             15.00%    
Period of notice for termination of license agreement     12 months            
Agenus | Development, Regulatory and Commercialization Milestones                  
License agreements                  
Additional milestone payments under the license agreement     $ 510,000            
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                  
License agreements                  
Royalty payments on future global net sales (as a percent)             6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                  
License agreements                  
Royalty payments on future global net sales (as a percent)             12.00%    
Agenus | Development Milestones                  
License agreements                  
Upfront payment under license agreement             $ 20,000    
Agenus                  
License agreements                  
Research and development expense             7,700 4,100  
Shares owned following stock purchase (as a percent) 11.00%       9.00%        
Ownership percentage (as a percent) 18.00%                
Unrealized loss on long term investments             (7,700) $ (3,000)  
Long term investment             63,800    
Total revenues                 22,600
Net income (loss)                 $ (127,000)
Agenus | Accrued and other liabilities                  
License agreements                  
Accrued and other liabilities             $ 8,300    
Agenus | Stock purchase agreement                  
License agreements                  
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0              
Purchase price of common stock   $ 60,000              
Per share price | $ / shares $ 4.40 $ 6.00              
Discount for lack of marketability $ 4,500                
Fair value of shares on the issuance date 39,500                
Total consideration paid 60,000                
Research and development expense 20,500                
Long term investment $ 39,500                
[1] The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date.